Pacira BioSciences, Inc. Common Stock
PCRX US6951271005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1% | -37% | -13% | -41% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Ceesay Abraham |
27.19 USD |
2,354 Sold |
64,005 USD |
04/09/2025 | 04/09/2025 |
| Bigal Marcelo |
23.67 USD |
4,912 Sold |
116,267 USD |
07/08/2025 | 07/08/2025 |
| Williams Kristen SR EXX |
26.24 USD |
14,376 Sold |
377,226 USD |
03/06/2025 | 04/06/2025 |
| Riker Lauren VP |
26.21 USD |
5,578 Sold |
146,208 USD |
03/06/2025 | 04/06/2025 |
| Slonin Jonathan CMO |
18.40 USD |
879 Sold |
16,174 USD |
02/01/2025 | 06/01/2025 |
| Gaugler Daryl COO |
19.76 USD |
500 Sold |
9,880 USD |
13/12/2024 | 13/12/2024 |
| Gaugler Daryl COO |
12.86 USD |
500 Sold |
6,430 USD |
13/09/2024 | 13/09/2024 |
| Bigal Marcelo |
13.25 USD |
1,512 Bought |
20,034 USD |
16/08/2024 | 16/08/2024 |
| Brege Laura |
12.81 USD |
1,000 Bought |
12,810 USD |
16/08/2024 | 16/08/2024 |
| Yang Michael J. |
12.90 USD |
2,000 Bought |
25,800 USD |
14/08/2024 | 14/08/2024 |